ARCT · Arcturus Therapeutics Holdings Inc. · Investor Relations
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-11-16 |
Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration
$50 Million Strategic Investment in Arcturus at an 80% Premium Proceeds to accelerate development of ARCT-2601 for OTC Deficiency and clinically validate Arcturus’ LUNAR 2.0™ next-generation mRNA platform SAN DIEGO --(BUSINESS WIRE)--Nov. 16, 2026-- Arcturus Therapeutics Holdings Inc. |
| 2026-11-05 |
Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
ARCT-032 (CF) Phase 2 enrollment completion YE 2026; data presentation Q2 2027 ARCT-2601 (OTC Deficiency), the first mRNA therapeutic candidate utilizing LUNAR 2.0™, Phase 2 dosing planned to begin Q1 2027; top-line data H2 2027 Investor conference call at 4:30 p.m. |
| 2026-10-26 |
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
SAN DIEGO --(BUSINESS WIRE)--Oct. 26, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced that it will release its financial results for the quarter |
| 2026-09-23 |
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 study LUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple NHP studies – unlocks new therapeutic opportunities ARCT-2601, an OTC deficiency |
| 2026-09-18 |
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
SAN DIEGO --(BUSINESS WIRE)--Sep. 18, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on |
| 2026-08-31 |
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the |
| 2026-08-06 |
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026 Arcturus regains global rights to KOSTAIVE® and infectious |
| 2026-07-28 |
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
SAN DIEGO --(BUSINESS WIRE)--Jul. 28, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for |
| 2026-07-20 |
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following |
| 2026-07-02 |
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights SAN DIEGO --(BUSINESS WIRE)--Jul. 2, 2026-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory |
| 2026-05-26 |
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
SAN DIEGO --(BUSINESS WIRE)--May 26, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following |
| 2026-05-07 |
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects Received regulatory direction on pediatric development strategy from FDA (Type C meeting) for ornithine |
| 2026-04-27 |
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
SAN DIEGO --(BUSINESS WIRE)--Apr. 27, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for |
| 2026-03-05 |
Arcturus Therapeutics to Attend Upcoming Investor Conference
SAN DIEGO --(BUSINESS WIRE)--Mar. 5, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the |
| 2026-03-03 |
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor conference call at 4:30 p.m. ET today SAN DIEGO --(BUSINESS WIRE)--Mar. |
Past events
Source: https://ir.arcturusrx.com/